Publication:
Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.

dc.contributor.authorGarrido Siles, Marga
dc.contributor.authorLópez-Beltran, Antonio
dc.contributor.authorPelechano, Paula
dc.contributor.authorGarcía Vicente, Ana María
dc.contributor.authorGironés Sarrió, Regina
dc.contributor.authorGonzález-Haba Peña, Eva
dc.contributor.authorRodríguez Antolín, Alfredo
dc.contributor.authorZapatero, Almudena
dc.contributor.authorArranz, José Ángel
dc.contributor.authorCliment, Miguel Ángel
dc.contributor.authorSpanish Oncology Genitourinary Multidisciplinary Working Group
dc.date.accessioned2023-05-03T13:51:34Z
dc.date.available2023-05-03T13:51:34Z
dc.date.issued2022-08-17
dc.description.abstractRecommendations regarding transversal topics applicable to bladder cancer patients independent of tumor grade and stage were established by members of the Spanish Oncology Genitourinary Multidisciplinary Working Group (SOGUG). Liquid biopsy in urine and blood samples is useful in the surveillance of non-muscle-invasive and muscle-invasive bladder cancer, respectively. Multiparametric MRI is an accurate, faster and non-invasive staging method overcoming the understaging risk of other procedures. The combination of FDG-PET/MRI could improve diagnostic reliability, but definite criteria for imaging interpretation are still unclear. Hospital oncology pharmacists as members of tumor committees improve the safety of drug use. Additionally, safety recommendations during BCG preparation should be strictly followed. The initial evaluation of patients with bladder cancer should include a multidimensional geriatric assessment. Orthotopic neobladder reconstruction should be offered to motivated patients with full information of self-care requirements. Bladder-sparing protocols, including chemoradiation therapy and immune checkpoints inhibitors (ICIs), should be implemented in centers with well-coordinated multidisciplinary teams and offered to selected patients. The optimal strategy of treatment with ICIs should be defined from the initial diagnostic phase with indications based on scientific evidence. Centralized protocols combined with the experience of professional groups are needed for the integral care of bladder cancer patients.
dc.identifier.doi10.3390/cancers14163968
dc.identifier.issn2072-6694
dc.identifier.pmcPMC9406347
dc.identifier.pmid36010964
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406347/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/14/16/3968/pdf?version=1660730546
dc.identifier.urihttp://hdl.handle.net/10668/20913
dc.issue.number16
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectbladder cancer
dc.subjectimaging techniques
dc.subjectimmune checkpoints inhibitors
dc.subjectliquid biopsy
dc.subjectsafety drug administration
dc.titleAdvances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9406347.pdf
Size:
2.56 MB
Format:
Adobe Portable Document Format